Fate Therapeutics reports preliminary Phase 1 results for FT836 solid tumor CAR-T therapy at ASCO

• Fate Therapeutics flagged upcoming conference disclosures for early-stage data from its off-the-shelf CAR T-cell pipeline, with results scheduled for presentation at the 2026 ASCO and EULAR annual meetings.
• At ASCO on May 30, the company plans to show preliminary Phase 1 findings for FT836 in solid tumors, positioning the program as designed to address tumor resistance while reducing reliance on conditioning chemotherapy.
• At EULAR on June 4, Fate is set to present Phase 1 results for FT819 in systemic lupus erythematosus, highlighting a safety and efficacy profile intended to support reduced conditioning and same-day discharge.
• A separate EULAR oral presentation the same day will outline FT839, an off-the-shelf dual-CAR approach aimed at targeting both B and T cells in autoimmune disease without preconditioning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605210830PRIMZONEFULLFEED9724354) on May 21, 2026, and is solely responsible for the information contained therein.